[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f84qOo8DgY25-qusx5fBmaEyi7s7dy5pu_Eqvb2fB5wE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":64,"rows":71},"Instituto de Oftalmología Fundación Conde de Valenciana",[4],42,false,12,2,3107,6,23,[14,17,19,22,24,26,28,31],{"name":15,"count":16},"Keratoconus",4,{"name":18,"count":16},"Dry Eye",{"name":20,"count":21},"Pterygium",3,{"name":23,"count":9},"Conjunctivitis, Allergic",{"name":25,"count":9},"Pterygium of Both Eyes",{"name":27,"count":9},"Recurrent Pterygium",{"name":29,"count":30},"Thyroid Eye Disease, TED",1,{"name":32,"count":30},"Scar Formation",[34,39,44,49,54,59],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06931041","Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial","2025-06-01","insulin lispro",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07376148","Fractional CO2 Laser-assisted Delivery of Hyaluronic Acid, Ascorbic Acid and Sodium DNA For Enhancing Facial Skin Quality in Individuals Over the Age of 30","2026-02-28","topical hyaluronic acid, ascorbic acid, and sodium DNA following ablative fractional laser treatment",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT07372014","A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treatment of Epiphora Associated With Lacrimal Punctum Stenosis","2026-03-02","Nepafenac and lubricant",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT07387536","The Effectiveness of Topical Silicone Application Combined With Photoprotection in the Development of Scarring Following Blepharoplasty","2026-03-31","Silicone-based topical formulation with sunscreen (SPF 50) application",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT07397520","The Application of Intralesional 5-fluorouracil for the Management of Hypertrophic Facial Scars in the Periocular Region Resulting From Trauma and Surgical Procedures in Individuals Aged Over 18 Years","2026-05-31","Intralesional administration of 5-fluorouracil",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT07178600","Clinical Determinants and Adverse Reactions to Tropicamide\u002FPhenylephrine in Hospitalized Patients.","2026-09","Ophthalmic administration of tropicamide\u002Fphenylephrine 8 mg\u002F50 mg\u002FmL.",[65,66,67,68,69,70],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[72,94,117,138,162,183,209,238,256,281,306,331,356,374,399,426,444,469,494,531,555,580],{"intervention":53,"totalTrials":30,"cells":73},{"EARLY_PHASE1":74,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":83,"NA":92},{"trials":75,"activeCount":76},[],0,{"trials":78,"activeCount":76},[],{"trials":80,"activeCount":76},[],{"trials":82,"activeCount":76},[],{"trials":84,"activeCount":30,"soonestReadout":52},[85],{"nctId":50,"briefTitle":51,"status":86,"phases":87,"primaryCompletion":52,"completion":57,"start":88,"enrollment":89,"conditions":90,"interventions":91},"RECRUITING",[69],"2025-10-01",30,[32],[53],{"trials":93,"activeCount":76},[],{"intervention":43,"totalTrials":30,"cells":95},{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":115},{"trials":97,"activeCount":76},[],{"trials":99,"activeCount":76},[],{"trials":101,"activeCount":76},[],{"trials":103,"activeCount":76},[],{"trials":105,"activeCount":30,"soonestReadout":42},[106],{"nctId":40,"briefTitle":41,"status":86,"phases":107,"primaryCompletion":42,"completion":108,"start":109,"enrollment":89,"conditions":110,"interventions":114},[69],"2026-04-30","2025-11-07",[111,112,113],"Skin Quality Improvement","Photo-aged Skin","Drug Delivery Systems",[43],{"trials":116,"activeCount":76},[],{"intervention":58,"totalTrials":30,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":127,"NA":136},{"trials":120,"activeCount":76},[],{"trials":122,"activeCount":76},[],{"trials":124,"activeCount":76},[],{"trials":126,"activeCount":76},[],{"trials":128,"activeCount":30,"soonestReadout":57},[129],{"nctId":55,"briefTitle":56,"status":86,"phases":130,"primaryCompletion":57,"completion":131,"start":132,"enrollment":89,"conditions":133,"interventions":135},[69],"2026-08-31","2025-08-01",[134],"Facial Scarring",[58],{"trials":137,"activeCount":76},[],{"intervention":48,"totalTrials":30,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":160},{"trials":141,"activeCount":76},[],{"trials":143,"activeCount":76},[],{"trials":145,"activeCount":76},[],{"trials":147,"activeCount":76},[],{"trials":149,"activeCount":30,"soonestReadout":47},[150],{"nctId":45,"briefTitle":46,"status":151,"phases":152,"primaryCompletion":47,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":159},"ACTIVE_NOT_RECRUITING",[69],"2026-05-29","2026-01-12",68,[157,158],"Epiphora","Punctal Stenosis",[48],{"trials":161,"activeCount":76},[],{"intervention":38,"totalTrials":30,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":179,"NA":181},{"trials":165,"activeCount":76},[],{"trials":167,"activeCount":76},[],{"trials":169,"activeCount":76},[],{"trials":171,"activeCount":30,"soonestReadout":37},[172],{"nctId":35,"briefTitle":36,"status":151,"phases":173,"primaryCompletion":37,"completion":37,"start":174,"enrollment":175,"conditions":176,"interventions":178},[68],"2024-02-01",25,[18,177],"Sjogren Syndrome",[38],{"trials":180,"activeCount":76},[],{"trials":182,"activeCount":76},[],{"intervention":63,"totalTrials":30,"cells":184},{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":186,"activeCount":76},[],{"trials":188,"activeCount":76},[],{"trials":190,"activeCount":76},[],{"trials":192,"activeCount":76},[],{"trials":194,"activeCount":76},[],{"trials":196,"activeCount":30,"soonestReadout":62},[197],{"nctId":60,"briefTitle":61,"status":86,"phases":198,"primaryCompletion":62,"completion":62,"start":199,"enrollment":200,"conditions":201,"interventions":208},[],"2023-09-02",1000,[202,203,204,205,206,207],"Adverse Drug Effect","Phenylephrine","Hypertension","Cardiovascular Complication","Ophthalmology","Ocular Discomfort",[63],{"intervention":210,"totalTrials":30,"cells":211},"Onabotulinum toxin A",{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":236},{"trials":213,"activeCount":76},[],{"trials":215,"activeCount":76},[],{"trials":217,"activeCount":76},[],{"trials":219,"activeCount":76},[],{"trials":221,"activeCount":76},[222],{"nctId":223,"briefTitle":224,"status":225,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":234},"NCT05840445","Efficacy of Prabotulinum and Onabotulinum Toxin-A for Facial Wrinkles","COMPLETED",[69],"2021-01-15","2020-06-15",26,[231,232,233],"Face","Skin Fold","Rejuvenation",[210,235],"Prabotulinumtoxin A",{"trials":237,"activeCount":76},[],{"intervention":235,"totalTrials":30,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":248,"NA":254},{"trials":241,"activeCount":76},[],{"trials":243,"activeCount":76},[],{"trials":245,"activeCount":76},[],{"trials":247,"activeCount":76},[],{"trials":249,"activeCount":76},[250],{"nctId":223,"briefTitle":224,"status":225,"phases":251,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":252,"interventions":253},[69],[231,232,233],[210,235],{"trials":255,"activeCount":76},[],{"intervention":257,"totalTrials":30,"cells":258},"Duosomal chemical peel application",{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":279},{"trials":260,"activeCount":76},[],{"trials":262,"activeCount":76},[],{"trials":264,"activeCount":76},[],{"trials":266,"activeCount":76},[],{"trials":268,"activeCount":76},[269],{"nctId":270,"briefTitle":271,"status":225,"phases":272,"primaryCompletion":273,"completion":274,"start":275,"enrollment":8,"conditions":276,"interventions":278},"NCT07401342","An Assessment of the Efficacy and Safety of Employing a Duosomal Chemical Peel for Aesthetic Enhancement in the Periocular and Facial Regions",[69],"2023-12-28","2024-01-31","2023-11-01",[277],"Chemical Peeling",[257],{"trials":280,"activeCount":76},[],{"intervention":282,"totalTrials":30,"cells":283},"Topical lyophilized exosomes application",{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":292,"NA":304},{"trials":285,"activeCount":76},[],{"trials":287,"activeCount":76},[],{"trials":289,"activeCount":76},[],{"trials":291,"activeCount":76},[],{"trials":293,"activeCount":76},[294],{"nctId":295,"briefTitle":296,"status":225,"phases":297,"primaryCompletion":298,"completion":299,"start":300,"enrollment":89,"conditions":301,"interventions":303},"NCT07372001","Effects on Facial Skin Aging After Topical Application of Exosomes With a Microneedling Device",[69],"2024-12-01","2025-03-01","2024-07-01",[302],"Skin Aging",[282],{"trials":305,"activeCount":76},[],{"intervention":307,"totalTrials":30,"cells":308},"Eyelid Cleansing with Wipes Containing Topical Chlorhexidine",{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":317,"NA":329},{"trials":310,"activeCount":76},[],{"trials":312,"activeCount":76},[],{"trials":314,"activeCount":76},[],{"trials":316,"activeCount":76},[],{"trials":318,"activeCount":76},[319],{"nctId":320,"briefTitle":321,"status":225,"phases":322,"primaryCompletion":323,"completion":324,"start":300,"enrollment":325,"conditions":326,"interventions":328},"NCT07451678","Treatment of Blepharitis Induced by Demodex Folliculorum Through Eyelid Cleansing With Wipes Containing Topical Chlorhexidine",[69],"2024-08-01","2025-01-31",106,[327],"Blepharitis",[307],{"trials":330,"activeCount":76},[],{"intervention":332,"totalTrials":30,"cells":333},"Gabapentin",{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":338,"PHASE3":340,"PHASE4":342,"NA":354},{"trials":335,"activeCount":76},[],{"trials":337,"activeCount":76},[],{"trials":339,"activeCount":76},[],{"trials":341,"activeCount":76},[],{"trials":343,"activeCount":76},[344],{"nctId":345,"briefTitle":346,"status":225,"phases":347,"primaryCompletion":348,"completion":348,"start":349,"enrollment":175,"conditions":350,"interventions":352},"NCT02867176","Pain Management in Corneal Collagen Crosslinking for Keratoconus",[69],"2016-07","2016-01",[351],"Pain",[332,353],"Ketorolac",{"trials":355,"activeCount":76},[],{"intervention":353,"totalTrials":30,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":372},{"trials":359,"activeCount":76},[],{"trials":361,"activeCount":76},[],{"trials":363,"activeCount":76},[],{"trials":365,"activeCount":76},[],{"trials":367,"activeCount":76},[368],{"nctId":345,"briefTitle":346,"status":225,"phases":369,"primaryCompletion":348,"completion":348,"start":349,"enrollment":175,"conditions":370,"interventions":371},[69],[351],[332,353],{"trials":373,"activeCount":76},[],{"intervention":375,"totalTrials":30,"cells":376},"Subconjuntival bevacizumab",{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":397},{"trials":378,"activeCount":76},[],{"trials":380,"activeCount":76},[381],{"nctId":382,"briefTitle":383,"status":225,"phases":384,"primaryCompletion":385,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":390},"NCT01686529","Bevacizumab for Primary Pterygium Treatment",[66],"2011-02","2012-02","2010-03",49,[20],[375],{"trials":392,"activeCount":76},[],{"trials":394,"activeCount":76},[],{"trials":396,"activeCount":76},[],{"trials":398,"activeCount":76},[],{"intervention":400,"totalTrials":30,"cells":401},"Besifloxacin Ophthalmic",{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":424},{"trials":403,"activeCount":76},[],{"trials":405,"activeCount":76},[406],{"nctId":407,"briefTitle":408,"status":225,"phases":409,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":416},"NCT04542759","Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery",[66],"2017-04","2017-01",60,[414,415],"Microbial Disease","Cataract Senile",[400,417],"Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution",{"trials":419,"activeCount":76},[],{"trials":421,"activeCount":76},[],{"trials":423,"activeCount":76},[],{"trials":425,"activeCount":76},[],{"intervention":417,"totalTrials":30,"cells":427},{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":429,"activeCount":76},[],{"trials":431,"activeCount":76},[432],{"nctId":407,"briefTitle":408,"status":225,"phases":433,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":434,"interventions":435},[66],[414,415],[400,417],{"trials":437,"activeCount":76},[],{"trials":439,"activeCount":76},[],{"trials":441,"activeCount":76},[],{"trials":443,"activeCount":76},[],{"intervention":445,"totalTrials":30,"cells":446},"Treatment posterior to surgery",{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":461,"PHASE3":463,"PHASE4":465,"NA":467},{"trials":448,"activeCount":76},[],{"trials":450,"activeCount":76},[451],{"nctId":452,"briefTitle":453,"status":225,"phases":454,"primaryCompletion":455,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":460},"NCT02625467","Treatment of Keratoconus With PALK Versus PK",[66],"2014-06","2015-11","2013-06",28,[15],[445],{"trials":462,"activeCount":76},[],{"trials":464,"activeCount":76},[],{"trials":466,"activeCount":76},[],{"trials":468,"activeCount":76},[],{"intervention":470,"totalTrials":30,"cells":471},"Liposomal Sirolimus",{"EARLY_PHASE1":472,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":490,"NA":492},{"trials":473,"activeCount":76},[474],{"nctId":475,"briefTitle":476,"status":225,"phases":477,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":483},"NCT04115800","Liposomal Sirolimus in Dry Eye Disease",[65],"2020-05-01","2020-08-01","2019-10-02",52,[18],[470],{"trials":485,"activeCount":76},[],{"trials":487,"activeCount":76},[],{"trials":489,"activeCount":76},[],{"trials":491,"activeCount":76},[],{"trials":493,"activeCount":76},[],{"intervention":495,"totalTrials":9,"cells":496},"Botulinum Toxin Type A",{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":519},{"trials":498,"activeCount":76},[],{"trials":500,"activeCount":76},[501],{"nctId":502,"briefTitle":503,"status":225,"phases":504,"primaryCompletion":505,"completion":506,"start":507,"enrollment":508,"conditions":509,"interventions":511},"NCT02403219","Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye",[66],"2014-02","2015-01","2013-05",20,[510],"Dry Eye Syndromes",[512],"Botulinum toxin type A",{"trials":514,"activeCount":76},[],{"trials":516,"activeCount":76},[],{"trials":518,"activeCount":76},[],{"trials":520,"activeCount":76},[521],{"nctId":522,"briefTitle":523,"status":225,"phases":524,"primaryCompletion":525,"completion":525,"start":526,"enrollment":89,"conditions":527,"interventions":530},"NCT07526870","Intradermal Microbotulinum Toxin for Sebum Reduction and Facial Pore Improvement",[70],"2024-11-24","2024-07-24",[528,529],"Facial Aging","Facial Wrinkles and Rhytides Reduction",[495],{"intervention":532,"totalTrials":30,"cells":533},"Triamcinolone Acetonide",{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":544},{"trials":535,"activeCount":76},[],{"trials":537,"activeCount":76},[],{"trials":539,"activeCount":76},[],{"trials":541,"activeCount":76},[],{"trials":543,"activeCount":76},[],{"trials":545,"activeCount":76},[546],{"nctId":547,"briefTitle":548,"status":225,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":554},"NCT07471997","Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye Disease",[70],"2025-02-20","2024-06-20",15,[29],[532],{"intervention":556,"totalTrials":30,"cells":557},"Bevacizumab",{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":566,"NA":568},{"trials":559,"activeCount":76},[],{"trials":561,"activeCount":76},[],{"trials":563,"activeCount":76},[],{"trials":565,"activeCount":76},[],{"trials":567,"activeCount":76},[],{"trials":569,"activeCount":76},[570],{"nctId":571,"briefTitle":572,"status":225,"phases":573,"primaryCompletion":574,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":578},"NCT02007174","Bevacizumab Injection for Recurrent Pterygium",[],"2013-08","2012-03",38,[27],[556,579,579],"Medical Treatment",{"intervention":579,"totalTrials":30,"cells":581},{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":583,"activeCount":76},[],{"trials":585,"activeCount":76},[],{"trials":587,"activeCount":76},[],{"trials":589,"activeCount":76},[],{"trials":591,"activeCount":76},[],{"trials":593,"activeCount":76},[594],{"nctId":571,"briefTitle":572,"status":225,"phases":595,"primaryCompletion":574,"completion":574,"start":575,"enrollment":576,"conditions":596,"interventions":597},[],[27],[556,579,579]]